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INTRODUCTION
INCIDENCE AND GEOGRAPHIC VARIATION
Colo-rectal  cancer  accounts for almost  10 % cancer  mortality in the United  
States.  In  almost  all  countries  age  standardized  incidence  rates  are  less  for  
women  than  in  men.  In  the  US alone  colo-rectal  cancer  is  the  second  most  
common  cause  of  cancer  mortality  and  ranks  third  in  frequency  of  cancer 
sites  in  both  men  and  women  (1,  2,  3).  Incidence  and  mortality  rates  are  
the  greatest  in  developed  western  nations.  Chinese  immigrants  in  the  US 
have  been  observed  with  higher  colo-rectal  cancer  rates.  This  has  been 
attributed  to  their  increased  meat  consumption  and  decreased  physical 
activity.  There  is  now  a  decrease  in  colo-rectal  cancer  incidence  and  
mortali ty  possibly  due  to  alterations  in  dietary  and  lifestyle  factors  and 
enhanced  use  of  colonoscopy  with  polypectomy  (4,  5,  6).  The  crude  
incidence  of  rectal  cancer  in  the  European  Union  is  approximately  one  
third  of  the  total  colorectal  cancer  incidence,  i.e.  15–25/100,000  per  year.  
The  mortality  is  4–10/100,000  per  year  with  the  lower  ﬁgures  valid  for  
females  and  the  higher  for  males.  Hence  environmental  exposure  in  colo-
rectal  cancer  is  of  great  importance  and  due  attention  should  be  paid  to  
dietary  and  lifestyle  modification  as  a  preventive  measure  (7).  Peak 
incidence  rates  are  noted  in  Europe,  US,  Australia  and  New  Zealand  (8).  
The lowest incidence rates are noted in India and South America.
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Madras Metropolitan Tumour Registry (MMTR) data
Crude incidence rate per 100,000 population (2006)
AGE MALE FEMALE
20-24 2.1 0.6
25-29 1.2 -
30-35 1.9 1.0
36-39 1.0 1.5
40-44 4.3 1.4
45-49 4.0 6.1
50-54 10.1 2.9
55-59 10.6 5.3
60-64 15.4 9.6
65-69 11.5 12.7
70-74 15.7 12.9
75+ 15.1 12.6
The  crude  incidence  rates  of  rectal  carcinoma  as  recorded  in  the  Madras 
metropolitan  Tumour  Registry  were  3.3/100,000  in  males  and  2.1/100,000 
in females during the year 2006.
RACE AND ETHNICITY
An  inherited  APC  gene  mutation,  11307K,  confers  a  higher  risk  of  colo-
rectal  cancer  within  certain  Ashkenazi  jewish  families  (9),  but  not  very 
apparent  in  other  ethnic  groups.  Inherited  mutations  in  the  DNA mismatch 
repair genes may be more common among African Americans (10).
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ETIOLOGY
Many factors  contribute to  the etiology of  colo-rectal  cancer.  It  is  complex 
and involves interplay of environmental and genetic factors (4, 6).
Environmental factors (22,23,24)
Increased Incidence Decreased Incidence
High-calorie diet Antioxidant vitamin consumption
High red meat consumption Consumption of fresh fruit and vegetables
Overcooked red meat consumption Use of nonsteroidal antiinflammatory drugs
High saturated fat consumption
Excess alcohol consumption
High-calcium diet
Cigarette smoking  
Sedentary lifestyle  
Obesity  
Note: Coffee or tea consumption has no effect on incidence.
Family History
Family  history  confers  an  increased  lifetime  risk  of  colo-rectal  cancer. 
About  15%  of  all  colo-rectal  cancers  occur  in  patients  with  a  history  of 
colo-rectal cancer in first degree relatives (11, 12, 13).
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Genes
The  functions  of  the  major  colon  cancer  genes  have  been  reasonably  well  
characterized over the past decade.   Three proposed classes of colon cancer 
genes  are  tumour  suppressor  genes,  oncogenes,  and  stability  genes  (15, 
16).  Tumour  suppressor  genes  constitute  the  most  important  class  of  genes  
responsible  for  hereditary  cancer  syndromes  and  represent  the  class  of 
genes  responsible  for  both  familial  adenomatous  polyposis  (FAP)  and 
juvenile  polyposis,  among  others  (17,  18,  19,  20).  Germline  mutations  of  
oncogenes  are  not  an  important  cause  of  inherited  susceptibili ty  to 
colorectal  cancer,  even  though  somatic  mutations  in  oncogenes  are  
ubiquitous  in  virtually  all  forms  of  gastrointestinal  cancers.  Stabili ty 
genes,  especially  the  mismatch  repair  genes  responsible  for  Lynch 
syndrome  (also  called  hereditary  nonpolyposis  colorectal  cancer 
[HNPCC]),  account  for  a  substantial  fraction  of  hereditary  colorectal  
cancer,  as  noted  below  (21).  MYH is  another  important  example  of  a 
stability  gene  that  confers  risk  of  colorectal  cancer  on  the  basis  of 
defective base excision repair. 
Following  table  summarizes  the  genes  that  confer  a  substantial  risk  of 
colorectal  cancer,  with  their  corresponding  a bsolute  risks  of  colorectal 
cancer  for  mutation  carriers  in  hereditary colorectal  cancer  syndromes (25,  
26, 27, 28)
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Gene Syndrome Hereditary Pattern
Predominant 
Cancer
Tumor suppressor genes
APC  FAP Dominant Colon, intestine, etc.
AXIN2  Attenuated polyposis Dominant Colon
TP53  (p53) Li-Fraumeni  Dominant Multiple (including colon)
STK11  Peutz-Jeghers  Dominant Multiple (including intestine)
PTEN  Cowden Dominant Multiple (including intestine)
BMPR1A  Juvenile polyposis Dominant Gastrointestinal
SMAD4  (DPC4) Juvenile polyposis Dominant Gastrointestinal
Repair/Stability genes
hMLH1 ,  hMSH2 ,  
hMSH6 ,  PMS2 Lynch Dominant
Multiple (including 
colon, uterus,  and 
others)
MYH  (MutYH) Attenuated polyposis Recessive Colon
BLM  Bloom Recessive Multiple (including colon)
Gene Syndrome Hereditary Pattern
Predominant 
Cancer
Oncogenes
KIT  Familial  GI stromal tumor GI stromal tumors
PDGFRA  Familial  GI stromal tumor GI stromal tumors
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Syndrome Absolute Risk in Mutation Carriers
FAP 90% by age 45 years 
Attenuated FAP 69% by age 80 years 
Lynch 80% by age 75 years  
MYH-associated neoplasia Not established
Peutz-Jeghers 39% by age 70 years 
Juvenile polyposis 17% to 68% by age 60 years 
APC gene  on chromosome  5q21 encodes  a  2,843-amino  acid  protein  that  is 
important in cell adhesion and signal transduction; beta-catenin is i ts major  
downstream  target.  APC is  a  tumour  suppressor  gene,  and  the  loss 
of APC is  among  the  earliest  events  in  the  chromosomal  instability  (CIN) 
colorectal  tumour  pathway.  The  important  role  of  APC in  predisposit ion  to 
colorectal  tumours  is  supported  by  the  association 
of APC germline  mutations  with  FAP  and  attenuated  FAP  (AFAP).  Both 
conditions can be diagnosed genetically by testing for   germline mutations 
in  the APC gene  in  DNA  from  peripheral  blood  leukocytes.  Most 
FAP pedigrees  have APC alterations  that  produce  truncating  mutations, 
primarily  in  the  first  half  of  the  gene.  AFAP is  associated  with  truncating 
mutations  primarily in the 5’ and 3’ ends of the gene and possibly  missense 
mutations  elsewhere.
Molecular Events Associated With Colon Carcinogenesis
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The  transit ion  from  normal  epithelium  to  adenoma  to  carcinoma  is  
associated  with  acquired  molecular  events  [29].  This  tumour  progression 
model  was  deduced  from comparison  of  genetic  alterations  seen  in  normal  
colon  epithelium,  adenomas  of  progressively  larger  size,  and  malignancies 
[30].  At  least  five  to  seven  major  deleterious  molecular  alterations  may 
occur  when  a  normal  epithelial  cell  progresses  in  a  clonal  fashion  to 
carcinoma. There are at least  two major pathways by which these molecular 
events  can  lead  to  colorectal  cancer.  About  85%  of  colorectal  cancers  are 
due  to  events  that  result  in  chromosomal  instabili ty  (CIN)  and  the 
remaining  15%  are  due  to  events  that  result  in  microsatelli te  instabili ty 
(MSI or MIN, also known as replication error).
The  spectrum  of  somatic  mutations  contributing  to  the  pathogenesis  of  
colorectal  cancer  is  likely  to  be  far  more  extensive  than  previously 
appreciated.  A comprehensive study that sequenced more than 13,000 genes 
in  a  series  of  colorectal  cancers  found that  tumours  accumulate  an  average 
of  approximately  90  mutant  genes.  Sixty-nine  genes  were  highlighted  as 
relevant  to  the  pathogenesis  of  colorectal  cancer,  and individual  colorectal  
cancers harboured an average of nine mutant genes per tumour.  In addition, 
each  tumour  studied  had  a  distinct  mutational  gene  signature.  Key changes 
in  CIN  cancers  include  widespread  alterations  in  chromosome  number 
(aneuploidy)  and  detectable  losses  at  the  molecular  level  of  portions  of 
chromosome  5q,  chromosome  18q,  and  chromosome  17p;  and  mutation  of 
the KRAS oncogene.
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Genetic polymorphism
This  may  be  of  great  importance.  The  changes  in  glutathion  s-transferase,  
ethylene  tetrahydrofolate  reductase and N-acetyl  transferases  cause genetic 
polymorphism.  Though  genetic  polymorphism  may  vary  among  different 
racial  and  ethnic  groups,  it  may  provide  some  clue  regarding  geographic  
variation of colo-rectal  cancer [31, 32, 33].
ANATOMY
The  colo-rectum  consists  of  caecum,  ascending  colon,  hepatic  flexure,  
transverse  colon,  splenic  flexure,  descending  colon,  sigmoid  colon  and 
rectum [34].
The  sigmoid  colon  evolves  distally  into  the  rectum  and  the  peritoneal  
coverage  recedes.  The  rectum  measures  12  to  15  cm  in  length,  extends  
from  the  recto-sigmoid  junction  to  the  pubo-rectalis  ring.  The  upper  third 
of  the  rectum  is  draped  with  peritoneum  anteriorly  and  onto  both  sides 
[35].  In  the  middle  third  of  the  rectum the  anterior  surface  is  covered  with  
peritoneum,  which  forms the posterior-border  of  the  recto-uterine pouch or  
recto-vesical  space.  The  lower  third  of  the  rectum  is  devoid  of  peritoneal 
covering and is in close proximity to adjacent structures including the bony 
pelvis. Distal  rectal  tumours have no serosal barrier  to invasion of adjacent 
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structures.
The  true  surgical  rectum begins  at  the  ano-rectal  ring  just  proximal  to  the  
dentate  line.  This  represents  the  internal  anal  sphincteric  muscle  which  is  
responsible for anal continence.
The  middle  valve  of  Houston  is  a  landmark  identified  endoscopically 
(usually  about  6  cm  from  the  ano-rectal  ring)  and  can  be  used  to 
differentiate  proximal  tumours  from  more  distal  lesions.  Fascia  of 
Waldeyer  separates  rectum  from  prostrate  and  fascia  of  Denonvill iers  is 
present on the posterior aspect along the last two sacral vertebrae.
Lymphatic drainage of the upper rectum follows the superior rectal  vessels,  
and  empty  into  the  inferior  mesenteric  node  and  those  of  the  middle  and 
lower  rectum along  the  middle  rectal  vessels  and  terminate  in  the  internal  
il iac  nodes.  The lowest  part  of  the  rectum and upper  part  of  the  anal  canal  
share  a  plexus  that  drains  to  lymphatics  that  accompany the  inferior  rectal  
and  internal  pudendal  blood  vessels  and  ult imately  drain  to  internal  il iac  
nodes [35].  
Lymphatics of the rectum
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Carcinomas of the lower rectum or those extending into the anal  canal  may 
occasionally  metastasize  to  superficial  inguinal  nodes  via  connections  to  
efferent  lymphatics  draining  the  lower  anus.  The  blood  supply  for  the  
rectum is by superior,  middle and inferior rectal  arteries.
STAGING
The  staging  of  colorectal  cancers  is  complicated  by  the  fact  that  multiple 
staging  systems  are  in  use  and  there  is  no  agreement  on  which  staging 
system should be used.  Although most  staging systems rely on the depth of  
tumour  invasion  and  absence  or  presence  of  nodal  and  distant  metastases,  
there  is  no  consensus  on  how  various  categories  should  be  grouped.  Since  
the description of the first practical staging system by Dukes, the evolution  
and  modification  of  staging systems over  last  60  years  with  newer  systems 
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using  similar  notations  to  represent  different  stages  has  resulted  in 
considerable  confusion  and  misinterpretation.   Apart  from  the  Dukes’  
system  [36]  which  is  still  widely  used,  the  other  popular  systems  include  
the  classification  described  by  Astler  and  Coller  [37],  and  the  tumour-
node-metastasis  (TNM) classification of  the Union Internationale  Contra  le  
Cancer  (UICC)  [38]  and  the  American  Joint  Committee  on  Cancer  (AJCC) 
[39]. 
The Dukes’ Staging System 
The  original  Dukes’ system  was  described  for  rectal  carcinomas  that  can  
also be applied to carcinomas of the colon [40].
Dukes’ Staging System
Stage  A tumours  were  defined  as  those  l imited  to  the  wall  (not  extending  
beyond  muscularis  propria),  stage  B  as  those  extending  through  the  wall 
(into  subserosa and/or  serosa,  or  extra-rectal  tissues),  and stage  C as  those 
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having  lymph  node metastasis.  The  stage  C was  later  subdivided  by Dukes 
himself  into  C1  when  only  perirectal  nodes  were  positive  and  C2  when 
nodes  at  the point  of  mesenteric  blood vessel  ligature  (called apical  nodes) 
were  involved.  The  stage  D  was  added  still  later  and  was  characterized  by 
presence of tumour beyond the l imits  of surgical resection.
The Astler-Coller Staging System 
This  system [37]  was  proposed in  1954 and has  resulted  in  some confusion 
because it  is often misinterpreted as related to the Dukes’ system.
Astler-Coller Staging System  
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The  original  scheme  had  five  stages,  A  was  limited  to  the  mucosa,  B1 
involved  muscularis  propria  but  did  not  penetrate  it,  B2  penetrated  the 
muscularis  propria,  and  C1  and  C2  were  counterparts  of  B1  and  B2  with  
nodal  metastases.  Since  then,  later  modifications  have  added  three  more  
stages.  B3  represents  involvement  of  adjacent  structures,  C3  is  B3  with 
nodal metastasis, and D signifies presence of distant metastasis. 
The TNM Staging System 
The systems described by AJCC and UICC using  TNM classifications  were  
unified  into  one  in  1988  [41].   The  latest  revision  (1997)  has  introduced  
some minor modifications.  The TNM system compartmentalizes carcinomas 
according  to  the  depth  of  invasion  of  the  primary  tumour,  the  absence  or  
presence  of  regional  lymph  node  metastases,  and  the  absence  or  presence  
of  distant  metastases.  The  possible  number  of  resulting  categories  is  too 
large (24 or more if  Tis  is  included)  for practical  usage.  Various  categories  
are  therefore  grouped  under  stages  I  through  IV.  ‘cTNM’  is  based  on 
evidence  acquired  before  treatment  and  ‘pTNM’  is  based  on  clinical 
staging  and  information  obtained  at  surgery  and  pathological  examination 
of the resected specimen.
Many  additional  descriptors  are  used  in  conjunction  with  the  TNM 
classification.  The  ‘R’  classification  refers  to  presence  of  residual 
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carcinoma  after  treatment.  The  ‘G’  classification  reflects  inclusion  of 
histological  grading.  The  ‘C’ factor  is  based  on  certainty  of  diagnosis,  ‘L’ 
represents  lymph  vessel  invasion,  and  ‘V’ reflects  venous  invasion.  It  is  
important  to  remember  that  a  minimum  of  twelve  lymph  nodes  should  be 
examined  for  proper  assessment  of  the  ‘N’ category [42].  A tumour  nodule 
measuring  three  cms  or  more  in  diameter  in  the  perirectal  or  pericolic  
adipose  tissue  even  without  histological  evidence  of  residual  lymph  node 
tissue in the nodule is classified as regional nodal metastasis.
TNM Staging System
TNM Staging Classification for Colorectal Carcinomas (1997)
TX Primary tumour can not be assessed.
T0 No primary tumour identified.
Tis Carcinoma in situ (tumour limited to mucosa).
T1 Involvement  of  submucosa,  but  no  penetration  through muscularis  propria.
T2 Invasion  into,  but  not  penetration  through,  muscularis propria.
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T3
Penetration  through  muscularis  propria  into  subserosa  (if 
present),  or  pericolic  fat,  but  not  into  peritoneal  cavity  or 
other organs.
T4 Invasion  of  other  organs  or  involvement  of  free  peritoneal cavity.
TNM Staging System
TNM Staging Classification for Colorectal Carcinomas (Contd.)
NX Nodal metastasis  can not be assessed.
N0 No nodal metastasis.
N1 1-3 pericolic / perirectal nodes involved.
N2 4 or more pericolic / perirectal  nodes involved.
MX Distant metastasis can not be assessed.
M0 No distant metastases.
M1 Distant metastases
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Stage Grouping criteria for TNM Classification (1997)
Stage 0 Tis N0 M0
Stage I T1-2 N0 M0
Stage II T3-4 N0 M0
Stage III any T N1-2 M0
Stage IV any T any N M1
Lymph Nodes designated as regional for colorectal carcinomas
Caecum Anterior caecal, posterior caecal,  ileocolic, right colic
Ascending colon Ileocolic, right colic,  middle colic
Hepatic flexure Middle colic, right colic
Transverse colon Middle colic
Splenic flexure Middle colic, left  colic, inferior mesenteric
Descending colon Left colic, inferior mesenteric,  sigmoid
Sigmoid colon Inferior mesenteric,  superior rectal,  sigmoidal, sigmoid mesenteric
Rectosigmoid
Perirectal,  left  colic, sigmoid mesenteric, 
sigmoidal,  inferior mesenteric, superior rectal, 
middle rectal
Rectum
Perirectal,  sigmoid mesenteric, inferior 
mesenteric,  lateral  sacral,  presacral, internal 
il iac,  sacral  promontory,  superior rectal,  middle 
rectal,  inferior rectal
The  metastatic  deposits  in  nodes  distant  from  those  surrounding  the  main 
tumour  or  its  main artery in  the  specimen (e.g.  external  iliac  or  para-aortic  
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nodes)  are  counted  as  distant  metastases  and  would  represent  M1.  The 
specified  regional  lymph  nodes  for  the  colorectal  cancers  for  different 
anatomical sites are given in the table above.
Other Staging Systems
Many other  staging  systems  have  been  proposed  trying  to  define  a  scheme 
which is more predictive.
The  Gunderson-Sosin  modification  of  the  Astler-Coller  system 
subclassifies  B2  and  C2  tumours  into  those  with  microscopic  (B2m  or  
C2m)  and  gross  (B2m+g  or  C2m+g)  invasion  of  tumour  through  the  bowel 
wall  [43].  The  Gastrointestinal  Tumour  Study  Group  (GITSG) 
classification  uses  the  number  of  nodes  (1-4  and  >4)  involved  to  separate 
stages  C1  and  C2,  respectively.  The  classification  by  Jass  et  al  uses 
absence  or  presence  of  transmural  penetration,  pushing  or  infiltrative 
margin  of  primary tumour,  absence  or  presence  of  conspicuous  peritumoral 
lymphocytic  infiltrate,  and  number  of  positive  nodes  for  a  mathematical 
stratification.
Many  other  local  and  insti tutional  schemes  exist  reflecting  target  the 
current controversies.  
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SYMPTOMS  AND  SIGNS  ASSOCIATED  WITH  COLORECTAL 
CANCER 
 Change in bowel habits
 Weight loss
 Change in appetite 
 Obstructive symptoms
 Palpable mass on digital  rectal examination
 Overt rectal  bleeding
 Microcytic anemia with fatigue,  shortness of breath, and angina
 Vague abdominal discomfort
 Large bowel obstruction
 Pneumaturia
 Feculent vaginal discharge
 Perforation (rare)
 Weakness
 Jaundice
 Ascites
HISTOLOGY 
 
More than 90% of cases are adenocarcinomas. 
Other histological types:
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 Squamous cell carcinoma
 Carcinoid
 Leiomyosarcoma
 Lymphoma
Most grading systems classify adenocarcinomas as either moderately or 
poorly differentiated.
PROGNOSTIC FACTORS
 Stage
 Histological grade
 Anatomic location of the tumour
 Clinical presentation
 Allelic loss of chromosome18q
  
Tumour  penetration  of  the  bowel  wall  and  lymph  node  involvement  are 
important  prognostic  factors  [44];  both  are  associated  with  increased  risk 
of  local  recurrence.  Absolute  number  and  proportion  of  involved  lymph 
nodes  are  important  predictors  of  outcome.  Presence  of  both  lymph  node  
involvement  and  extension  of  disease  beyond  the  bowel  wall  is  more  
ominous  than  the  presence  of  either  alone.  In  patients  with  low  rectal  
cancer  being  considered  for  sphincter-sparing  treatment,  clinical  mobili ty,  
size,  and  morphology  of  the  lesion  are  predictors  of  outcome.  Aneuploidy 
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and  high  proliferative  index  (measured  by  adding  percentage  of  cells  in  S 
phase  to  those  in  G2  and  M  phase)  are  associated  with  worse  survival  in  
colorectal cancer.
METASTASIS
Metastasis  is  usually  by  haematogenous  spread,  mainly  to  the  lung  and 
liver.  Pre-treatment  evaluation  is  valuable  for  proper  staging  and  for 
planning treatment [45].
 DIAGNOSTIC WORKUP FOR COLORECTAL CANCER
1. History 
2. Physical examination,  including detailed rectal examination 
3. Gynaecologic examination (female patients)
4. Radiographic and endoscopic studies 
a. Barium enema or colonoscopy 
b. Proctosigmoidoscopy (if  colonoscopy not done) 
c. Computed tomography or magnetic resonance imaging (pelvis, 
abdomen, if indicated) 
d. Intrarectal ultrasound (if indicated)
5. Routine laboratory studies 
a. Complete blood cell count 
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b. Blood chemistry profile,  including liver and renal function 
studies  
6. Radiogram chest
7. Carcinoembryonic antigen  
8. Molecular biologic markers 
Positron  emission  tomography  (PET)  scan  [55,  56],  magnetic  resonance  
imaging  (MRI),  and  ultrasound  may  be  useful  in  evaluating  patients  with  
oligometastatic  disease  who may be appropriate  candidates  for  resection of 
metastatic disease with curative intent.
CARCINOEMBRYONIC ANTIGEN
 
CEA is  a  cell-surface  glycoprotein  that  is  shed  into  the  blood  and  is  the 
best-known  serological  marker  for  monitoring  colorectal  cancer  disease  
status  and  for  detecting  early  recurrence  and  liver  metastases.  CEA is  too 
insensit ive  and  non-specific  to  be  valuable  for  screening  of  colorectal 
cancer.  Elevation  of  serum  CEA  levels,  however,  does  correlate  with  a 
number  of  parameters.  Higher  CEA levels  are  associated  with  histological  
grade  1  or  2  tumours,  more  advanced  stages  of  the  disease,  and  the  
presence  of  visceral  metastases.  Although  serum  CEA concentration  is  an 
independent  prognostic  factor,  its  putative  value  lies  in  serial  monitoring 
after surgical resection.
New markers ,  such as  CA 19-9,  may be  of  value  in  monitoring  recurrences  
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and  complement  CEA.  Monoclonal  antibodies  may  also  be  useful  in 
immuno-histo-chemical  staining  of  tissues.  The  presence  of  an  abnormal 
number  of  chromosomes  in  the  tumour  cells  (aneuploidy)  confers  a  worse  
prognosis  than  is  observed  in  patients  with  diploid  tumours.  Light 
microscopic  features  and  stage,  however,  remain  the  most  reliable 
prognostic  measures.  Early  reports  suggest  that  tumour  DNA  and 
circulating  tumour  cells  may  also  have  uti lity,  both  as  init ial  diagnostic  
tools and for early diagnosis of recurrent disease.
STAGING INVESTIGATIONS
The  staging  of  rectal  cancer  involves  identifying  the  depth  of  tumour  
penetration  through  the  rectal  wall  (T)  and  the  presence  or  absence  of  
diseased  lymph  nodes  (N)  and  detecting  distant  metastases  (M).  The 
preoperative  staging  of  rectal  cancer  is  based  on  the  TNM  system  of 
classification.  There  are  various  modalities  employed  for  staging  rectal 
cancer,  including  DRE,  endoscopic  ultrasonography  [47,  48],  computed 
tomography  (CT)  [49,  50],  and  magnetic  resonance  imaging  (MRI)  [51, 
52].  Each  method  has  its  own  strengths  and  limitations.  Optimally,  a  
combination of these methods should be used to mitigate these l imitations.  
Endorectal  ultrasound  and  MRI  are  commonly  used  to  assess  the  extent  of  
the  primary  tumour.  Nodal  status  can  be  determined  using  MRI,  CT,  and 
EUS, but may be difficult  to assess radiographically.
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Accuracy of Pelvic CT, MRI and EUS for T and N staging [46, 53]
‘T’ stage
Investigation Accuracy (%)
Sensitivity 
(%)
Specificity 
(%)
CT 73 78 63
ERUS 87 93 78
MRI 82 86 77
MRI-Endorectal  coil 84 89 79
‘N’ stage
Investigation Accuracy (%)
Sensitivity 
(%)
Specificity 
(%)
CT 66 52 78
ERUS 74 71 76
MRI 74 65 80
MRI-Endorectal  coil 82 82 83
Computerized Tomography (CT)
CT  has  been  utilized  extensively  and  is  part  of  the  routine  work-up  of 
patients.  CT appears  to  be  much more  useful  in  identifying enlarged pelvic 
lymph  nodes  and  metastasis  outside  the  pelvis  than  the  extent  or  stage  of 
the  primary  tumour.  Standard  CT  does  not  permit  the  visualization  of  the 
layers  of  the  rectal  wall,  and,  therefore,  its  uti lity  in  the  assessment  of 
primary cancers is limited.  The sensitivity of CT scan is reported as 50% to  
80%  accurate,  with  30%  to  80%  specificity  (65%  to  75%  accurate  for 
tumour  staging  and  55%  to  65%  accurate  in  mesorectal  lymph  node 
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staging).  The ability of CT scans for detecting distant metastasis,  including 
pelvic  and  para-aortic  lymph  nodes,  is  higher  than  for  detecting  perirectal  
nodal  involvement  (75%  to  87%  vs.  45%).  Any  lymphadenopathy  near  the 
rectum seen on a CT scan should be considered abnormal.
Endorectal ultrasound (EUS)
Transrectal ultrasound demonstrating the 5 concentric layers of the 
normal rectal wall
EUS is able to distinguish the five layers of the rectal wall with good spatial resolution. 
The mucosa (innermost ring),  the submucosa (middle ring),  and the serosa (outermost 
ring) are echogenic (white rings). They are separated by 2 hypoechoic (black) rings, the 
muscularis mucosa (adjacent to the mucosa) and the muscularis propria (adjacent to the 
serosa); the rings are best seen in the 5-o'clock position in the full-size view. The rectal 
wall is visualized as 5 concentric bands as follows:
1) Mucosa (echogenic)
2) Muscularis mucosa (hypoechoic)
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3) Submucosa (echogenic)
4) Muscularis propria (hypoechoic)
5) Serosa (echogenic)
Transrectal  endoscopic  ultrasound  techniques  have  been  more  helpful  in 
efforts  to  clinically  stage  rectal  cancers.  EUS can  be  80% to  95% accurate 
in  tumour  staging  and  70%  to  75%  accurate  in  mesorectal  lymph  node 
staging.  The  transrectal  ultrasound is  very good at  demonstrating  layers  of  
the  rectal  wall  especially  the  mucosa,  muscularis  mucosa,  submucosa,  and 
muscularis  propria.  Its  use  is  limited  to  lesions  <14  cm from the  anus  and 
not  applicable for the upper  rectum or for stenosing tumours.  EUS can also 
identify enlarged perirectal  lymph nodes  but  is  not  effective  outside  of  the  
perirectum.  One  area  where  EUS  can  be  very  useful  is  in  determining 
extension  of  disease  into  the  anal  canal,  which  is  an  area  that  is  poorly  
visualized  on  CT  but  of  critical  importance  for  planning  sphincter  
preserving surgical procedures.   
Magnetic Resonance Imaging (MRI)
Recently,  MRI  techniques  have  been  found  to  be  of  greater  accuracy  in 
defining  the  extent  of  rectal  cancer  extension  and  also  determining  the  
location  and  stage  of  tumour.  Different  approaches  to  MRI  have  been 
explored  including the  use  of  body coils,  endorectal  MRI and phased array 
techniques.  Although  MRI  appears  to  have  greater  accuracy,  it  requires  a  
significant  learning  curve  but  is  becoming  a  greater  part  of  the  standard 
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pre-surgical work-up for rectal cancer.
Body coil  MRI,  which  first  became available  in  the  mid-1980s,  has  had  an 
accuracy of  54% to  66% for  T staging,  but  this  has  improved  with  the  use 
of  endorectal  coil  MRI  with  reported  accuracy  rates  of  80%  to  95%.  A 
significant advantage of both endorectal coil  and surface coil  MRI is that it  
is  less  operator-dependent  and  permits  a  larger  field  of  view  than  EUS.  It  
also  allows  assessment  for  proximal  tumours  and  stenotic  lesions  where 
EUS  is  not  an  option.  Another  advantage  of  MRI  is  that  it  can  detect  
involved  lymph  nodes  on  the  basis  of  characteristics  other  than  size.  MRI 
can  also  be  very  helpful  in  determining  the  extent  of  lateral  extension  of 
disease,  which  is  critical  in  predicting  the  adequacy  of  circumferential  
margins for surgical excision.  Several studies using phased array MRI have 
reported  accuracy rates  of  80% to  97% in  predicting  lateral  disease  extent 
and  have  correlated  the  likelihood  of  tumour-free  resection  margin  by 
visualizing tumour involvement of the mesorectal  fascia.
TREATMENT
Preoperative  staging  is  crucial  for  determining  the  approach  in  the 
treatment  of  rectal  cancer.  In  the  last  two  decades,  the  treatment  of  rectal  
cancer has evolved from a single treatment to multiple options based on the  
disease  stage  at  diagnosis.  The  techniques  of  radical  resection  and 
reconstruction have been refined,  the role  and results  of local excisions are 
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better  defined,  and  neoadjuvant  treatment  has  decreased  the  rate  of  local  
recurrence  and  has  improved  survival  rates.  The  correct  staging  of  rectal  
lesions  helps  to  determine  the  appropriate  surgical  management  and  to  
identify  those  patients  who  would  benefit  from  preoperative  adjuvant  
therapy [54].
In early stage rectal carcinoma only surgery could be the treatment [61] but  
not for patients  with stage II or III rectal  cancer.  60%–80% of patients with 
rectal  cancer  have  tumours  that  are  large  and  biologically  aggressive.  
Disease  at  this  stage  carries  a  higher  risk  of  local  and systemic  recurrence  
after  treatment.  Accordingly,  strategies  have  been  developed  to  address  
these  issues  through  locoregional  resection  and  multimodality  therapy. 
However,  adequate  surgical  resection  and  choice  of  technique  are  the  most  
cri tical treatment factors determining patient outcome.
SURGERY 
The principles of surgical management of rectal cancer are:   
1) removal of the primary tumour with adequate margins of normal 
tissue,  
2) treatment of the draining lymphatics, and  
3) restoration of function.
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Transanal local excision
 This is  done for early cancers,  T1 lesions,  less than 3 cm in size,  well  differentiated 
tumours,  within  8  cm of  the  anal  verge,  encompassing  less  than  30% of  rectal  wall 
circumference with negative nodes.
Abdominoperineal resection (APR)
APR has  been  considered  the  gold  standard  for  surgical  resection  of  distal  
rectal  cancers  and  requires  removal  of  the  primary  tumour  along  with  a 
complete  proctectomy,  leading  to  a  permanent  colostomy.   APR  is 
associated  with  a  slightly  higher  morbidity  and  mortality  than  LAR  and  a 
worse  quality  of  life  due  to  the  presence  of  a  colostomy.  There  is  also  a  
higher  risk of  positive  margins  with  APR as  the  mesorectum is  very thin in 
the  distal  segment  of  the  rectum  and  lateral  margins  are  restricted  by  the 
close presence of the prostate in the male and vagina in females. 
Low Anterior Resection (LAR)
Sphincter  preservation  is  a  big step  towards  improving quality of  life  [60].  
Availability of  circular  stapling  devices  has  expanded the  role  of  sphincter  
preserving  surgical  options  in  rectal  cancers,  and  LARs  are  now  being 
performed not  just  for  cancers  of  the upper  third  of  the  rectum but  also for  
middle  and  lower  third  cancers.  About  2-cm  distal  margin  of  preserved  
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normal  rectum  is  considered  optimal  for  preservation  of  good  bowel 
function.  Patients  should  have  good  anal  sphincter  continence  prior  to  
considering  sphincter-preserving  options.  Patient  age,  pelvic  anatomy,  
gender,  and  body  habitus  can  affect  suitabili ty  for  sphincter  preservation. 
The  absence  of  a  colostomy,  while  offering  a  better  quality  of  life  with  
LAR,  can  be  compromised  with  bowel  urgency  and  frequency  or  poor 
sphincter control.  
Total mesorectal excision (TME)
The  mesorectum  is  defined  as  the  lymphatic,  vascular,  fatty,  and  neural 
tissues  that  are  circumferentially  adherent  to  the  rectum from the  level  of 
the  sacral  promontory to  the  levator  ani  muscles.  Lateral  spread  of  disease  
has  been  shown  to  occur  not  only  at  the  level  of  the  tumour  but  distally 
within  the mesorectum as  well.  Heald et  al  have  recommended that  en bloc  
removal  of  the  tumour  within  the  envelope  of  the  endopelvic  fascia  is 
necessary  to  obtain  adequate  lateral  clearance  of  disease  and  reduce  the 
likelihood  of  local  recurrence.  Total  mesorectal  excision,  as  they 
described,  has  now  become  the  established  standard  for  all  radical  rectal  
cancer  resections  and  requires  sharp  dissection  along  the  plane  that  
separates  the  visceral  from the  parietal  pelvic  fascia  with  complete  en  bloc 
removal of the rectum so that all  of the rectal mesentery remains within the  
envelope  of  the  specimen.  On  pathological  review,  an  adequate  dissection 
should  include  12  to  15  perirectal  and  pelvic  lymph  nodes.  Careful  nerve 
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sparring  dissection  with  TME  reduces  the  incidence  of  retrograde 
ejaculation.
A number  of  European  surgeons  have  advocated  TME.  They  claim  a  low 
local  recurrence  rate  but  have  also  noted  that  rectal  stump 
devascularization  results  in  a  higher  rate  of  postoperative  anastomotic  site  
leakage.  A recent report  indicated that  radiation after TME reduces the rate 
of  local  recurrence  at  2  years  from  the  t ime  of  surgery  suggesting  that 
radiation  is  still  a  valuable  tool  in  reducing local  recurrence  even after  the 
more extensive en bloc resection done with TME.
RADIOTHERAPY FIELDS AND TECHNIQUES
Patients  are  commonly  treated  with  a  three-field  technique  consisting  of  a 
PA  and  lateral  fields  [58,  59].  When  inclusion  of  the  anterior  pelvis  is  
indicated  (e.g.,  treatment  of  the  external  i liac  lymph  nodes)  an  additional  
AP field  may be  advantageous.  High-energy photons  and  appropriate  beam 
wedging  and  weighting  are  mandatory  to  ensure  a  homogenous  dose 
distribution within the pelvis.
Preoperative RT fields for a patient with cT3N1 carcinoma of the midrectum treated 
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with a three-field technique
Posteroanterior (PA) (A) and right lateral (B) fields which encompass the target volumes 
are devised (left lateral not shown).
PTV- planning target volume; GTV- gross tumor volume; CTV- clinical target volume
Traditional  field  design  has  been based on bony landmarks,  the  location  of  
contrast-enhanced  bowel  /  rectum  and  the  anal  verge.  The  superior  border  
of  the  PA (and  AP)  field(s)  generally  covers  the  sacral  promontory,  while 
the  inferior  border  is  placed  at  least  3  to  4  cm  distal  to  the  rectal  cancer.  
For  upper  rectal  cancers,  the  distal  border  need  not  include  the  entire  anal 
canal,  but  should  extend  to  the  dentate  l ine  (approximately  2  cm from the 
anal  verge)  so  that  all  the  mesorectum is  encompassed.  The  lateral  borders 
of  the  PA field  should  include  1.5-  to  2-cm margin beyond the pelvic  brim,  
with  appropriate  blocking  of  almost  all  of  the  femoral  head.  Lateral  fields  
should  cover  the  anterior  bony margin  of  sacrum with  1.5-  to  2-cm margin  
posteriorly  to  allow  for  setup  error  and  dosimetric  coverage.  Anteriorly,  
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the  field  includes  the  internal  il iac  lymph  nodes  by  placing  its  border  on 
the  posterior  edge  of  pubic  symphysis.  Care  is  taken,  however,  when 
devising this border to ensure at  least  3 cm coverage of the primary tumour 
anteriorly.  In  the  superior-anterior  portion  of  the  field,  it  is  usually  
possible  to  block a  portion of small  bowel.  Similarly,  the anterior  genitalia  
in most patients should be blocked in the lateral  fields.
Custom boost  fields  are  devised that  include the GTV (or  tumour bed)  with  
a  2-  to  3-cm  margin.  A three-field  technique  or  laterals  alone  will  often 
suffice.
CHEMOTHERAPY
The  treatment  of  rectal  cancer  has  evolved  substantially  over  the  past  two 
decades.  In  the  past,  rectal  cancer  was  frequently  treated  with  surgery 
alone,  which  resulted  in  high  rates  of  local  failure,  with  significant  patient 
morbidity  and  mortality.  Sentinel  trials  in  the  1980s  to  early  1990s 
demonstrated  that  adjuvant  chemoradiotherapy  resulted  in  lower  rates  of 
local  failure  and  superior  survival  versus  resection  alone  [62].  This 
observation  led  to  the  adoption  of  adjuvant  chemoradiotherapy  as  standard 
treatment for patients with stage II/III  disease.
Mitomycin C
Mitomycin  C,  isolated  from  Streptomyces  caespitosus,  was  introduced  in  
1958,  and  was  subsequently  shown  to  have  a  moderate  in  vitro  hypoxia  
selective  cytotoxicity.  The  cytotoxicity  of  mitomycin  C  is  associated  with 
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formation  of  monofunctional  alkylation  and  more  potently  with  intra-  and 
inter-strand  crosslinks  of  DNA,  all  of  which  require  bioreductive 
activation.  The  one-electron  reduction  of  mitomycin  C  results  in  a 
semiquinone,  which,  under  hypoxic  conditions,  activates  the  aziridine  ring 
and  results  in  binding  of  the  drug to  DNA .  Following the  initial  covalent  
attachment  of mitomycin C to DNA, the drug can undergo further  reductive 
activation  to  form  a  second  alkylating  site.  The  one-electron  reduction 
pathway  can  be  catalysed  by  any  of  several  enzymes  including  NADPH, 
cytochrome  P450  reductase   and  xanthine  oxidase  (Pan  et  al.  1984),  in  a 
process  that  can  be  reversed  by  O 2 .  Mitomycin  C  can  also  be  reductively 
activated  via  two-electron  reducing  DT-diaphorase  generating  an  O 2-
insensit ive  hydroquinone.  Despite  variable  results  in  hypoxia  selective 
cytotoxicity  observed  in  preclinical  studies,  clinical  trials  have  reported 
that  mitomycin C in combination with radiation shows a significant  benefit  
in  local  regional  control  rates  for  patients  with  head  and  neck  cancer.  It  is 
metabolized  mainly  in  the  liver  by  P450  system  and  DT-diaphorase  and 
excreted through the hepato-biliary system.
The toxicities of mitomycin C include:
 Myelosuppression
 Nausea and vomiting
 Skin necrosis,  being a vesicant drug 
 Alopecia
 Photosensitivity
 Haemolytic-uremia-like syndrome
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5-Flurouracil  (5-FU)
5-FU is an antimetabolite that was synthesized by Dr. Charles Heidelberger  
in  1957.  It  is  the  most  widely used  drug showing  wide  range of  activity  in  
broad range of  solid  tumours.  It  is  the  backbone for  various  regimens used  
to  treat  advanced  colorectal  cancer.  5-FU  enters  the  cells  via  uracil  
transport  mechanism and is  then anabolized to various cytotoxic nucleotide 
forms by several biochemical pathways.
5-FU exerts its  cytotoxic effects  through various mechanisms: 
a. inhibition  of  thymidylate  synthatase  leading  to  depletion  of 
deoxythymidine  triphosphate,  thus  interfering  with  DNA biosynthesis 
and repair
b. incorporation  into  RNA  resulting  in  alterations  in  RNA  processing 
and/or mRNA translation
c. incorporation  into  DNA resulting  in  inhibition  of  DNA synthesis  and 
function
In  addition  to  the  above  mechanisms,  TS  inhibit ion  may  also  activate  
programmed  cell  death  pathways  in  susceptible  cells  leading  to  parental 
DNA fragmentation.  5-FU  cytotoxicity  many  be  mediated  by  activation  of 
Fas-signalling  pathways.  It  is  cell  cycle  s-phase  specific  but  acts  in  other 
cell  cycle  phases  as  well.  5-FU  rapidly  enters  all  tissues  including  spinal  
fluid  and  malignant  effusions.  Most  of  the  drug  is  degraded  in  the  liver.  
Inactive  metabolites  are  excreted  in  urine,  bile  and breath.  The elimination  
half-life is short  - 10 to 20 minutes.
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The toxicities of 5-FU are more severe in patients with dihydro-pyrimidine 
dehydrogenase deficiency. They include:
 mylosuppression
 mucositis
 excessive lacrimation due to dacryocysti tis and lacrimal duct stenosis
 photosensit ivity
 reversible cerebellar dysfunction
 somnolence
 confusion or seizure
 oesophagitis
 hand-foot syndrome
 nausea and vomiting
 black hairy tongue
It  is  contraindicated  in  patients  of  active  ischemic  heart  disease  or  history  
of  myocardial  infarction  within  previous  six  months  and  in  those  patients  
who had grade III / IV mylosuppression.
NEOADJUVANT TREATMENT
The oncology community agrees  on combined modality therapy but  there is 
a  great  debate over  the neoadjuvant  versus  adjuvant  therapy.  Proponents  of 
neoadjuvant  therapy  believe  that  it  improves  sphincter  preservation  and 
thereby  quality  of  l ife,  allows  otherwise  unresectable  disease  to  be 
surgically  excised  [63]  and  delivers  improved  outcomes  of  local  control.  
Opponents  contend  that  the  surgical  procedures  are  made  more  difficult  
after  radiation,  healing  is  impaired  and  overtreatment  of  early  stage 
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patients occurs.  
Variations  in  the  use  of  RT  alone  or  combined  with  chemotherapy  and  in  
surgical  techniques  have  been  investigated  in  attempts  to  improve  local  
control rates. Numerous randomized controlled studies of both preoperative 
and postoperative RT alone have demonstrated no improvement  in survival;  
at  best,  there has been a small  decrease in the rate of local recurrence.
A number  of  European  surgeons  have  advocated  TME.  They  claim  a  low 
local  recurrence  rate  but  have  also  noted  that  rectal  stump 
devascularization  results  in  a  higher  rate  of  postoperative  anastomotic  site  
leakage.  A recent report  indicated that  radiation after TME reduces the rate 
of  local  recurrence  at  2  years  from  the  t ime  of  surgery  suggesting  that 
radiation  is  still  a  valuable  tool  in  reducing local  recurrence  even after  the 
more extensive en bloc resection done with TME.
Neoadjuvant radiotherapy
Neoadjuvant  radiotherapy  effectively  improves  local  control.  Biologically 
effective  dose  of  <30 Gy provides  significant  improvement  in  local  failure  
and survival (at  5 years), but it  does not improve overall  survival or rate of  
distant metastasis.
Dutch  colorectal  cancer  group  (CKV095-04)  compared  short  course  RT 
followed  by  TME  versus  TME  alone,  in  1861  patients  with  clinically 
resectable  disease.  A total  dose  of  25  Gy  in  five  fractions  was  delivered  
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over 5 days. There was a decrease in local recurrence at 2 years, which was  
maintained  til l  5  years.  The  overall  survival  rates  were  64.2%  and  63.5% 
which showed no benefit with RT followed by TME.
Swedish rectal  cancer  tr ial  randomized 1168 patients  with  resectable  rectal 
cancers  to  25  Gy  in  5  fractions  preoperatively  versus  surgery  alone.  At  5 
years,  recurrence  rates  were  12%  and  25%  respectively.  The  overall  
survival showed benefit  of 10% favouring preoperative RT.
French  Lyon  R96-02  trial  evaluated  T2  /  T3  rectal  cancer  by  comparing 
external  RT 39 Gy in 13 fractions  with same dose external  RT along with 3 
fractions  of  contact  x-ray boost  therapy up to  85 Gy.  A total  of  88  patients 
were  randomized.  A higher  complete  response  rate  was  noted  in  the  boost 
group  compared  with  the  no-boost  group  (24%  versus  2%  respectively). 
Sphincter preservation also improved in the boost arm.
Neoadjuvant chemoradiotherapy
The  effect  of  combined  preoperative  chemo-radiotherapy  has  been 
demonstrated in various trials.
The  EORTC  2291  trial  evaluated  1011  patients  with  resectable  T3  /  T4 
lesions.  Radiotherapy  consisted  of  45  Gy  over  5  weeks  and  chemotherapy 
consisted of  5-FU /  leucovorin for  5 days  for 2  cycles  preoperatively and 4 
cycles  postoperatively.  The  5-year  local  recurrence  rate  in  the  arm 
receiving  RT alone  was  17% while  it  was  8.5% in  chemoradiotherapy arm.  
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Overall survival was the same in both the arms.
The  German  rectal  cancer  study  group  evaluated  preoperative  versus 
postoperative  chemotherapy.  They  randomized  823  patients  to  receive 
preoperative  50  Gy RT along  with  infusional  5-FU during  RT and  4  cycles  
postoperatively.  Five  year  survival  was  same  in  both  arms,  but  it  showed 
local failure was higher in postoperative arm.
The French rectal  cancer  trial,  FFCD 9203,  compared preoperative  RT [64] 
and  preoperative  chemoradiation  [68]  in  733  patients.  They  received  
preoperative  RT 45 Gy over  5  weeks  with  or  without  5-FU /  LV during  the 
first  and  fifth  week  of  radiation.  At  5  years,  local  recurrence  rate  was  8% 
in chemoradiation arm and 16% in radiation only arm. Difference in overall  
survival was not significant.
The  New  England  Journal  of  Medicine  reported  a  trial  conducted  by  the 
North  Central  Cancer  Treatment  Group  (NCCTG  794751)  from  1980  to 
1986  which  served  as  the  basis  for  the  Consensus  Conference 
recommendations.  This  study  involved  the  participation  of  about  200 
patients.  Beginning four to ten weeks after curative intent surgery for stage 
II  or III  rectal  cancer,  patients were randomized to receive either combined 
modality  radiation  plus  chemotherapy  or  radiation  therapy  alone.  In  both 
treatment  regimens,  radiation  therapy  consisted  of  45  Gy  to  the  pelvis 
delivered  over  four  and  one-half  weeks  followed  by  a  5.4-Gy boost  to  the  
tumour  bed.  In  the  combined  modality  treatment,  patients  received  an 
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initial  nine-week cycle  of  5-FU and methyl-CCNU. This  chemotherapy was 
followed by radiation  plus  concurrent  5-FU. Patients  then  received another  
nine-week cycle of 5-FU and methyl-CCNU.
With further follow-up, the results  of this  study show a clear advantage for  
the  combined modality treatment  in  all  parameters  of  evaluation,  including 
reduced  overall  recurrences  (p=0.0016),  reduced  local  recurrences 
(p=0.036),  reduced  distant  metastases  (p=0.011),  and  improved  survival 
(p=0.026).  There  is  a  46% reduction  in  pelvic  recurrence,  a  37% reduction 
in  distant  tumour  spread,  and  a  29%  reduction  in  patient  deaths.  Severe 
acute  toxicity  was  infrequent.  Severe  delayed  reactions,  usually  bowel 
obstruction  requiring  surgical  intervention,  occurred  in  about  6.5%  of  all  
patients  and  were  comparable  in  incidence  whether  patients  received 
radiation therapy alone or radiation plus chemotherapy.
ADJUVANT TREATMENT
Postoperative Radiation Therapy
This  allows selection of  patients  with  high risk features  who would  benefit  
from  adjuvant  treatment.  The  disadvantage  includes  hypoxia  of  post-
surgical  tumour  bed  and  increased  small  bowel  in  pelvis  increasing  the  
toxicity.
43
Uppasala  trial  compared  short  course  preoperative  radiotherapy  25.5  Gy 
over 5 days to conventional fractionation 60 Gy over 8 weeks postoperative  
radiotherapy.  A  total  of  471  patients  were  randomized  in  this  study.  
Preoperative treatment  was well  tolerated and the local  recurrence rate  was 
less in the preoperative RT, 12% versus 21%.
Intergroup 0147 trials  evaluated  preoperative  versus  postoperative  therapy.  
It  closed early due to poor accrual.
Local  excision  followed  by  adjuvant  therapy  was  studied  by  Chakravarti  
et.al  (1999) on 99 patients  who underwent  transanal  excision – 47 received 
adjuvant  radiation,  26  patients  received  concurrent  5-FU.  Five-year  local  
control  and disease  free  survival  were  72% and 66% respectively,  and 90% 
and 74% for the adjuvant therapy group.
Postoperative chemotherapy
A  subset  analysis  of  select  T3N0  patients  without  adverse  features  were  
noted  to  have  no  benefit  from  local  radiotherapy.  This  group  may  be  best  
treated with surgery and adjuvant chemotherapy.
Postoperative chemoradiotherapy
The  commonly  employed  chemotherapy  schedule  in  combination  with 
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radiation  is  5-FU  based,  with  or  without  LV [65,  66,  67].  Two  Intergroup 
trials  (0114  and  0144)  evaluated  postoperative  5FU  based  regimens  with 
adjuvant RT. Both had similar end points.
Intergroup  0114  examined  1695  patients  with  T3/T4  and  node  positive  
disease  with  postoperative  adjuvant  chemotherapy  and  radiation  therapy. 
Patients  were  treated  with  2  cycles  of  chemotherapy  followed  by 
concurrent  chemoradiation 45 Gy,  with a  boost  to  50 to  54 Gy,  followed by 
2  final  cycles  of  chemotherapy.  No  difference  in  overall  survival,  disease 
free survival and local control was found.
Krook  et  al  evaluated  204  patients  with  deeply  invasive  or  node  positive  
rectal  cancer  with  postoperative  radiotherapy  (45  to  50  Gy)  alone  or  in 
combination  with  5-FU.  The  combined  modality  arm  showed  better 
improvement in local control and cancer specific death.
The  Gastrointestinal  Tumour  Study  group  (GITSG)  protocol  GI-7175 
randomized  227  patients  to  observation,  postoperative  chemotherapy, 
postoperative  radiotherapy  and  combined  chemotherapy  &  radiotherapy.  
Results  revealed  significant  improvement  in  combined  modality  treatment 
over no adjuvant therapy for time to recurrence.
The  most  effective  adjuvant  approach,  which  has  become standard  practice 
in  the  United  States,  employs  combined  5-FU  chemotherapy  and  RT.  This 
approach  has  significantly  reduced  the  rates  of  local  recurrence,  distant  
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metastasis,  and  cancer-related  deaths  among  patients  with  stage  II  and  III  
rectal  cancer.  The  addition  to  RT of  5-FU  (given  either  by  rapid  injection  
or  by  continuous  intravenous  infusion  throughout  the  period  of  radiation)  
apparently  was  crucial  to  the  marked  reduction  in  the  local  recurrence  of 
rectal  cancer.
The  current  standard  therapy  for  stage  II  and  III  rectal  cancer  is  5-FU 
bolus,  500 mg/m 2 /day for  5  days  each month for  2  months,  both before and 
after  RT.  During  RT  (5,040  cGy),  5-FU  is  given  as  a  radiosensitizer  at  a  
dose  of  225  mg/m 2 /day  by  continuous  IV  infusion.  The  addition  of  a 
nitrosourea,  levamisole,  or  leucovorin  to  the  regimen  did  not  improve  the 
results.
Preoperative versus postoperative RT
Treatment  with  RT  and  5-FU  sensit ization  is  becoming  more  and  more 
common  as  a  preoperative  strategy  to  reduce  the  likelihood  of  incomplete  
resections  and  to  downstage  disease  in  patients  with  fixed  (T4)  or  node-
positive disease as indicated by endorectal  ultrasound and biopsy.
BRACHYTHERAPY
Intraoperative interstit ial  and endocavitary radiation improves local control 
in  locally  advanced  and  recurrent  rectal  cancers  [69].  10  to  12.5  Gy  were 
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given  for  complete  resection,  12.5  to  15  Gy  for  microscopic  residual,  and  
17.5 to 20 Gy for gross residual disease.  The 5-year local control was 90%, 
65%,  55%,  and  the  disease  specific  survival  at  5  years  was  65%,  45%,  and  
15%,  for  these  three  dose  levels,  respectively.  IORT  improved  local 
control.
Memorial  Sloan  Kettering  Cancer  Hospital  treated  68  patients,  over  a  4-
year  period,  for  locally  advanced  unresectable  rectal  cancer  with 
neoadjuvant  5-FU/LV followed by surgery and IORT.  High dose  rate  IORT,  
consisting  of  10  to  20  Gy,  was  delivered  using  Harrison-Anderson-Mick 
applicator.  Median  follow  up  was  17.5  months.  81%  patients  had  local  
control  at  2  years.  For  patients  with  recurrent  disease  the  2-year  local 
control rate was 63%.
INTRAOPERATIVE ELECTRON THERAPY (IOERT)
Massachusetts  General  Hospital  studied  73  patients  with  locally  advanced 
rectal  cancer  who  received  IOERT  due  to  tumour  adherence  or  residual  
disease  [70].  Patients  received  neoadjuvant  RT with  concurrent  5-FU.  At  5  
years,  local  control  was  associated  with  the  extent  of  resection.  Complete 
resection  and  IOERT  yielded  better  results;  local  control  and  disease 
specific  survival  of  89%  and  63%  respectively  compared  with  65%  and 
32%  in  28  patients  undergoing  IOERT  for  residual  disease.  The  5-year  
complication rate was 11%.
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Predictive value of 18F-FDG PET in the management of rectal cancers
18F-FDG  PET has  a  high  predictive  value  in  the  therapeutic  management  
of colorectal  cancer.  This technique could be an asset for improving patient  
care  by  reducing  the  effort,  costs,  and  morbidity  associated  with  the  
treatment  in  nonresponders.  The  available  studies  on  chemotherapy 
response  monitoring  in  advanced  colorectal  cancer  and  on  preoperative  
radiotherapy  and  multimodality  treatment  response  evaluation  in  primary 
rectal  cancer  indicate  that  18F-FDG  PET  is  a  signiﬁcant  predictor  of 
therapy outcome in both situations. In primary rectal  cancer,  18F-FDG PET 
is  applicable  after  neoadjuvant  treatment  in  a  preoperative  setting  
(important  for  the  preoperative  selection  for  an  individually  tailored 
surgical  approach)  and  correlates  better  with  pathology  than  morphologic 
imaging modalities.
Interestingly,  when  18F-FDG  PET  is  able  to  predict  the  ﬁnal  outcome,  it  
may be used to guide adjuvant chemotherapy for rectal  cancer after  optimal 
neoadjuvant and local treatments.
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BACKGROUND OF THE PRESENT STUDY
At Cancer Institute,  the usual protocol for locally advanced rectal  cancer is 
neo-adjuvant  chemo-radiation  followed  by  surgery.  The  chemotherapy 
schedule  used  is  Mitomycin-c  and  5-Flurouracil  concurrently  with 
radiation.  In  order  to  analyze  the  effect  of  this  multimodal  approach,  this 
study was planned. 
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AIM OF THE STUDY
To  study  the  outcome  of  patients  with  locally  advanced  rectal  cancer 
treated  with  neo-adjuvant  chemotherapy  and  radiotherapy  at  the  Institute  
from 2002 to 2006.
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MATERIAL AND METHODS
224 patients  with  locally  advanced  (T2-T4/N0-N2  disease),  pathologically 
confirmed  adenocarcinoma  of  the  rectum,  without  detectable  distant  
metastasis  at  presentation,  and who were registered at  the Institute between 
January  2002  to  December  2006,  were  taken  up  for  the  study.  Those 
patients who had already undergone specific treatment  for the rectal  cancer  
were not included.
Pre-treatment Workup
The pre-treatment workup included:
 Detailed history
 Complete physical examination including detailed rectal examination
 Hematology and biochemistry
 Chest X Ray, ECG and Echo
 Colonoscopy
 Histopathological examination
 CT Scan Abdomen and pelvis
 CEA
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Treatment Protocol
After  taking  an  informed  consent,  patients  were  taken  up  for  first  cycle  of  
chemotherapy  with  Mitomycin  C  and  5-Flurouracil  from  day  1  to  day  5 
followed  by  radiotherapy.  At  30  Gy  of  RT,  patients  received  second  cycle  
of chemotherapy with 5-FU (x 5 days)  only.  Radiotherapy was continued to 
a  total  of  50  Gy.  Patients  were  reassesed  six  weeks  after  the  end  of 
chemoradiation for surgery.  In suitable  patients,  either an APR or LAR was  
done,  depending  upon  the  clinical  situation.  Following  surgery,  they 
received  adjuvant  5-FU based chemotherapy,  once  in  3  weeks,  to  a  total  of 
6 cycles. 
Radiotherapy protocol
Radiation  was  given  with  6-MV Xrays,  with  ‘4  fields  box’ technique  (AP / 
PA /  2  Laterals),  delivering  200  cGy per  fraction,  to  a  total  dose  50  Gy to 
the whole pelvis after  simulation.
Chemotherapy protocol
The firct  cycle of chemotherapy included:
Inj Mitomycin C at a dose of 6 mg/m 2  IV on day 1, and
Inj 5-Flurouracil  at a dose of 375 mg/m 2  IV on day 1 to day 5
In the second cycle, Inj Mitomycin C was not given.
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RESULTS
A  total  of  224  patients  with  locally  advanced  (T2-T4/N0-N2  disease), 
pathologically confirmed adenocarcinoma of the rectum, without detectable 
distant  metastasis,  registered  at  the  Institute  between  January  2002  to  
December 2006, were taken up for this  study.
AGE-WISE DISTRIBUTION
The age of these patients varied from 21 yrs to 90 yrs. Majority of the patients were in the 
6th decade of life as shown below:
GENDER-WISE DISTRIBUTION
There were 141 (62.9%) male patients and 83 (37.1%) female patients in 
the study. The male:female ratio was 1.7:1.
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STAGE-WISE DISTRIBUTION
The following table shows the stage-wise distribution of these patients:
Stage Number of patients
II A 158
II B 25
III A 4
III B 32
III C 5
  TREATMENT
The  treatment  details  of  the  224  patients  taken  up  for  this  study are  given 
in the following table:
Treatment
Patients
No %
Neoadjuvant chemoradiation followed by reassessment 
for surgery 182 81.3
Straight surgery 42 18.7
The  details  of  further  management  of  the  182  patients  who  had  completed  
the neoadjuvant chemoradiation are given in the following table:
Details  of the patients
Patients
No %
Patients who underwent the planned radical surgery 122 67.0
Patients who were kept on observation only as CR was 
2 1.1
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achieved with neoadjuvant chemoradiation
Patients who were advised surgery but declined it 42
23.1
Patients who were not considered suitable for surgery 16
8.8
3-year DFS & OS in 122 patients who completed the planned treatment 
(Neoadjuvant chemoradiation followed by surgery)
Result
Patients
No %
3-year DFS 82 67.2
3-year OS 95 77.9
Patients on observation (N=2)
Both  the  patients,  who  achieved  CR with  chemoradiation  itself,  were  only 
on  meticulous  followup  with  no  reactivation  of  disease  for  more  than  3 
years.
Patients who declined surgery (N=42)
11  of  42  patients  who  declined  surgery  after  neoadjuvant  chemoradiation 
(26.2%) were alive for 3 years or beyond. 
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DISCUSSION
Variations in  the use of RT alone or  in  combination with chemotherapy and 
in  surgical  techniques  have  been  investigated  in  attempts  to  improve  local  
control rates. Numerous randomized controlled studies of both preoperative 
and postoperative RT alone have demonstrated no improvement  in survival;  
at  best,  there has  been a  small  decrease in  the rate  of local  recurrence.  The  
addition  of  chemotherapy  along  with  radiotherapy  gives  an  added 
advantage  in  steril izing  microscopic  disease  in  regions  that  either  cannot 
be  resected  or  ought  to  be  spared.  Neoadjuvant  chemoradiation  has  helped 
down-staging  the  disease,  increased  sphincter  preservation  surgeries  and 
thus  leads  to  better  quality  of  life  in  a  locally  advanced  rectal  cancer  
patient.  In  addition it  decreased tumour seedling at  the time of surgery and  
thus  improved  overall  survival.  The  advantages  of  neoadjuvant 
chemoradiation  do not  end here.  There is  increased radio-sensitivity due to  
more  oxygenated  cells  and  absence  of  postsurgical  morbidities  and 
possibili ty of converting APR to LAR.
NSABP  R  –  03  trial  compared  neoadjuvant  versus  adjuvant 
chemoradiotherapy in the treatement  of locally advanced rectal  cancer.  The 
trial  randomly  assigned  123  patients  to  preoperative  chemoradiotherapy 
and 131 patients to post operative chemoradiotherapy. The 5 -  year DFS for 
preoperative  patients  was 64.7% and for  postoperative  patients  was  53.4%. 
The  5  –  year  OS  rates  were  74.5%  vs  65.6%  respectively.  The  study 
concluded  that  preoperative  chemoradiotherapy  compared  with 
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postoperative chemoradiotherapy significantly improved DFS and showed a 
trend towards improved OS (75).
At  the  Institute,  neoadjuvant  therapy  has  been  in  practice  for  the  last  50 
years  in  head  and  neck  cancers.  The  same  was  later  introduced  in  the 
management  of  breast  cancers  also.  The  pathological  and  local  response 
has  been  significant  in  these  malignancies.  In  the  same  way,  neoadjuvant  
chemoration  followed  by  radical  surgery  has  shown  very  satisfactory 
results  in the management of locally advanced rectal cancers.
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CONCLUSION
Neoadjuvant  chemoration  followed  by  radical  surgery  has  shown  very 
satisfactory results  in the management of locally advanced rectal cancers.
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FUTURE DIRECTION
The  evolution  of  the  multidisciplinary  approach  to  the  management  of 
rectal  cancer  has  resulted  in  significant  improvements  in  disease-free  and 
overall  survival  rates.  Significant  enhancements  in  sphincter  preservation 
and  quality  of  life  have  also  been  realized.  The  challenge  is  to  further  
improve these endpoints  through the multidisciplinary approach.  Molecular  
targeted  therapies  such  as  bevacizumab  and  cetuximab  represent  key 
components  of  evolving  treatment  paradigms.  Novel  radiation  techniques 
such  as  IMRT and  novel  surgical  techniques  may  also  further  improve  the  
care of the rectal cancer patient.
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